William W. Greenfield
Professor
Also affiliated: Arkansas Children's Hospital (2014); University of Arkansas Medical Center (2015–2021); Arkansas Department of Health (2021–2024)
Obstetrics & Gynecology, College of Medicine
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Dr. William W. Greenfield's research focuses on human papillomavirus (HPV) and its association with cervical intraepithelial neoplasia and cervical cancer. He has investigated the impact of therapeutic HPV vaccines, examining immune responses, viral load reduction, and cross-protection mechanisms. His work includes clinical trials, such as a phase I dose-escalation study of a peptide-based HPV therapeutic vaccine with a novel adjuvant for women with cervical intraepithelial neoplasia 2/3. Dr. Greenfield has also explored the relationship between HPV type 16 viral load, CD4+ and CD8+ T-cell responses, and favorable clinical trends in affected patients. Additionally, his research interests extend to the cervical microbiome's role in vaccine response and has included a study on low-grade fibromyxoid sarcoma presenting as a primary ovarian neoplasm. He has also contributed to research on improving perinatal regionalization and lowering infant mortality through telemedicine collaboration.
Research Overview
Dr. William Greenfield completed his medical degree at Meharry Medical College in Nashville, Tennessee, completed an internship at Baylor College of Medicine in Houston, Texas, and his residency in Obstetrics and Gynecology at the University of Arkansas for Medical Sciences in Little Rock. Before attending medical school, he received a pharmacy degree from Auburn University. His clinical interests are in obstetrics and gynecology. He is trained in daVinci Robotic Surgery. He has made presentations nationally, regionally and locally on topics in his field. Dr. Greenfield currently serves as the Arkansas Section Chair for the American Congress of Obstetrics and Gynecology, and is a member of several professional organizations including:Arkansas Medical SocietyAmerican Medical AssociationAmerican Society of Colposcopy and Cervical PathologyDr. Greenfield enjoys both his obstetric and gynecologic patients. He likes to help educate his patients and guide them to make informed decisions about their healthcare.
Metrics
- h-index: 11
- Publications: 28
- Citations: 415
Positions
-
Professor publications 2007–2026University of Arkansas for Medical Sciences Obstetrics & Gynecology, College of Medicine Institutional directory
Selected Publications
-
Maternity Care Team Members’ Perspectives on Barriers and Facilitators to Integrating Doulas into the Hospital Setting (2026)
-
Personal Birth Experiences and Clinician Attitudes About Cesarean Birth: A Cross‐Sectional Study With Female Labor and Delivery Unit Staff (2026)
-
A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or Candida (2025)
-
Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus Candida adjuvant alone in treating cervical intraepithelial neoplasia 2/3. (2024)
-
Public Maternal Health Dashboards in the United States: Descriptive Assessment (2024)
-
Maternal Mortality Review Committee findings: awareness and recommended dissemination strategies in Arkansas (2024)
-
A peptide-based human papillomavirus therapeutic vaccine, PepCan, or Candida adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3). (2023)
-
Quarantine and isolation facility: A State Health Department’s response to the COVID-19 pandemic (2021)
-
Evaluation of DNA extraction protocols from liquid-based cytology specimens for studying cervical microbiota (2021)
-
Evaluation of DNA extraction protocols from liquid-based cytology specimens for studying cervical microbiota (2020)
-
Cervical Microbiome and Response to a Human Papillomavirus Therapeutic Vaccine for Treating High-Grade Cervical Squamous Intraepithelial Lesion (2019)
-
Cervical microbiome role in outcomes of therapeutic HPV vaccination for cervical intraepithelial neoplasia. (2018)
-
Human papillomavirus type 16 viral load is decreased following a therapeutic vaccination (2016)
-
A phase I dose-escalation clinical trial of a peptide-based human papillomavirus therapeutic vaccine with candida skin test reagent as a novel vaccine adjuvant for treating women with biopsy-proven cervical intraepithelial neoplasia 2/3. (2015)
-
A novel use of a statewide telecolposcopy network for recruitment of participants in a Phase I clinical trial of a human papillomavirus therapeutic vaccine (2015)
Grants & Funding
As listed on this researcher's institutional profile.
- DP24-004, PRC, Core: Health Promotion and Disease Prevention Research Centers NIH Co-Investigator
- Understanding and Enhancing T-Cell Responses to High Risk Human Papillomaviruses-Renewal NIH Co-Investigator
- The Arkansas Perinatal Quality Collaborative Centers for Disease Control & Prevention Co-Principal Investigator
Collaboration Network
Top Collaborators
- Human papillomavirus type 16 viral load is decreased following a therapeutic vaccination
- A phase I dose-escalation clinical trial of a peptide-based human papillomavirus therapeutic vaccine with Candida skin test reagent as a novel vaccine adjuvant for treating women with biopsy-proven cervical intraepithelial neoplasia 2/3
- CD4+ T-cell response against human papillomavirus type 16 E6 protein is associated with a favorable clinical trend
- Cross-Reactivity, Epitope Spreading, andDe NovoImmune Stimulation Are Possible Mechanisms of Cross-Protection of Nonvaccine Human Papillomavirus (HPV) Types in Recipients of HPV Therapeutic Vaccines
- A Favorable Clinical Trend Is Associated With CD8 T-Cell Immune Responses to the Human Papillomavirus Type 16 E6 Antigens in Women Being Studied for Abnormal Pap Smear Results
Showing 5 of 16 shared publications
- Human papillomavirus type 16 viral load is decreased following a therapeutic vaccination
- A phase I dose-escalation clinical trial of a peptide-based human papillomavirus therapeutic vaccine with Candida skin test reagent as a novel vaccine adjuvant for treating women with biopsy-proven cervical intraepithelial neoplasia 2/3
- CD4+ T-cell response against human papillomavirus type 16 E6 protein is associated with a favorable clinical trend
- Cross-Reactivity, Epitope Spreading, andDe NovoImmune Stimulation Are Possible Mechanisms of Cross-Protection of Nonvaccine Human Papillomavirus (HPV) Types in Recipients of HPV Therapeutic Vaccines
- A Favorable Clinical Trend Is Associated With CD8 T-Cell Immune Responses to the Human Papillomavirus Type 16 E6 Antigens in Women Being Studied for Abnormal Pap Smear Results
Showing 5 of 14 shared publications
- Human papillomavirus type 16 viral load is decreased following a therapeutic vaccination
- A phase I dose-escalation clinical trial of a peptide-based human papillomavirus therapeutic vaccine with Candida skin test reagent as a novel vaccine adjuvant for treating women with biopsy-proven cervical intraepithelial neoplasia 2/3
- CD4+ T-cell response against human papillomavirus type 16 E6 protein is associated with a favorable clinical trend
- Cervical Microbiome and Response to a Human Papillomavirus Therapeutic Vaccine for Treating High-Grade Cervical Squamous Intraepithelial Lesion
- A novel use of a statewide telecolposcopy network for recruitment of participants in a Phase I clinical trial of a human papillomavirus therapeutic vaccine
Showing 5 of 8 shared publications
- Human papillomavirus type 16 viral load is decreased following a therapeutic vaccination
- A phase I dose-escalation clinical trial of a peptide-based human papillomavirus therapeutic vaccine with Candida skin test reagent as a novel vaccine adjuvant for treating women with biopsy-proven cervical intraepithelial neoplasia 2/3
- A novel use of a statewide telecolposcopy network for recruitment of participants in a Phase I clinical trial of a human papillomavirus therapeutic vaccine
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or Candida
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or Candida adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
Showing 5 of 6 shared publications
- A phase I dose-escalation clinical trial of a peptide-based human papillomavirus therapeutic vaccine with Candida skin test reagent as a novel vaccine adjuvant for treating women with biopsy-proven cervical intraepithelial neoplasia 2/3
- A phase I dose-escalation clinical trial of a peptide-based human papillomavirus therapeutic vaccine with candida skin test reagent as a novel vaccine adjuvant for treating women with biopsy-proven cervical intraepithelial neoplasia 2/3.
- Maternal Mortality Review Committee findings: awareness and recommended dissemination strategies in Arkansas
- Personal Birth Experiences and Clinician Attitudes About Cesarean Birth: A Cross‐Sectional Study With Female Labor and Delivery Unit Staff
- Maternity Care Team Members’ Perspectives on Barriers and Facilitators to Integrating Doulas into the Hospital Setting
- Cervical Microbiome and Response to a Human Papillomavirus Therapeutic Vaccine for Treating High-Grade Cervical Squamous Intraepithelial Lesion
- Evaluation of DNA extraction protocols from liquid-based cytology specimens for studying cervical microbiota
- Evaluation of DNA extraction protocols from liquid-based cytology specimens for studying cervical microbiota
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or Candida
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or Candida adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- Evaluation of DNA extraction protocols from liquid-based cytology specimens for studying cervical microbiota
- Evaluation of DNA extraction protocols from liquid-based cytology specimens for studying cervical microbiota
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or Candida
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or Candida adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus Candida adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
- Human papillomavirus type 16 viral load is decreased following a therapeutic vaccination
- A phase I dose-escalation clinical trial of a peptide-based human papillomavirus therapeutic vaccine with Candida skin test reagent as a novel vaccine adjuvant for treating women with biopsy-proven cervical intraepithelial neoplasia 2/3
- Cross-Reactivity, Epitope Spreading, andDe NovoImmune Stimulation Are Possible Mechanisms of Cross-Protection of Nonvaccine Human Papillomavirus (HPV) Types in Recipients of HPV Therapeutic Vaccines
- A phase I dose-escalation clinical trial of a peptide-based human papillomavirus therapeutic vaccine with candida skin test reagent as a novel vaccine adjuvant for treating women with biopsy-proven cervical intraepithelial neoplasia 2/3.
- Human papillomavirus type 16 viral load is decreased following a therapeutic vaccination
- A phase I dose-escalation clinical trial of a peptide-based human papillomavirus therapeutic vaccine with Candida skin test reagent as a novel vaccine adjuvant for treating women with biopsy-proven cervical intraepithelial neoplasia 2/3
- A novel use of a statewide telecolposcopy network for recruitment of participants in a Phase I clinical trial of a human papillomavirus therapeutic vaccine
- A phase I dose-escalation clinical trial of a peptide-based human papillomavirus therapeutic vaccine with candida skin test reagent as a novel vaccine adjuvant for treating women with biopsy-proven cervical intraepithelial neoplasia 2/3.
- Human papillomavirus type 16 viral load is decreased following a therapeutic vaccination
- A phase I dose-escalation clinical trial of a peptide-based human papillomavirus therapeutic vaccine with Candida skin test reagent as a novel vaccine adjuvant for treating women with biopsy-proven cervical intraepithelial neoplasia 2/3
- A novel use of a statewide telecolposcopy network for recruitment of participants in a Phase I clinical trial of a human papillomavirus therapeutic vaccine
- A phase I dose-escalation clinical trial of a peptide-based human papillomavirus therapeutic vaccine with candida skin test reagent as a novel vaccine adjuvant for treating women with biopsy-proven cervical intraepithelial neoplasia 2/3.
- Human papillomavirus type 16 viral load is decreased following a therapeutic vaccination
- A phase I dose-escalation clinical trial of a peptide-based human papillomavirus therapeutic vaccine with Candida skin test reagent as a novel vaccine adjuvant for treating women with biopsy-proven cervical intraepithelial neoplasia 2/3
- A phase I dose-escalation clinical trial of a peptide-based human papillomavirus therapeutic vaccine with candida skin test reagent as a novel vaccine adjuvant for treating women with biopsy-proven cervical intraepithelial neoplasia 2/3.
- A phase I dose-escalation clinical trial of a peptide-based human papillomavirus therapeutic vaccine with Candida skin test reagent as a novel vaccine adjuvant for treating women with biopsy-proven cervical intraepithelial neoplasia 2/3
- A phase I dose-escalation clinical trial of a peptide-based human papillomavirus therapeutic vaccine with candida skin test reagent as a novel vaccine adjuvant for treating women with biopsy-proven cervical intraepithelial neoplasia 2/3.
- Personal Birth Experiences and Clinician Attitudes About Cesarean Birth: A Cross‐Sectional Study With Female Labor and Delivery Unit Staff
- A phase I dose-escalation clinical trial of a peptide-based human papillomavirus therapeutic vaccine with Candida skin test reagent as a novel vaccine adjuvant for treating women with biopsy-proven cervical intraepithelial neoplasia 2/3
- A novel use of a statewide telecolposcopy network for recruitment of participants in a Phase I clinical trial of a human papillomavirus therapeutic vaccine
- A phase I dose-escalation clinical trial of a peptide-based human papillomavirus therapeutic vaccine with candida skin test reagent as a novel vaccine adjuvant for treating women with biopsy-proven cervical intraepithelial neoplasia 2/3.
- Human papillomavirus type 16 viral load is decreased following a therapeutic vaccination
- A phase I dose-escalation clinical trial of a peptide-based human papillomavirus therapeutic vaccine with Candida skin test reagent as a novel vaccine adjuvant for treating women with biopsy-proven cervical intraepithelial neoplasia 2/3
- A phase I dose-escalation clinical trial of a peptide-based human papillomavirus therapeutic vaccine with candida skin test reagent as a novel vaccine adjuvant for treating women with biopsy-proven cervical intraepithelial neoplasia 2/3.
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or Candida
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or Candida adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus Candida adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
Similar Researchers
Based on overlapping research topics